One Programme, Two Journeys: Rethinking Patient Support Strategy Across European Markets

Reading time: 7 minuti
Ask a room full of pharmaceutical executives to define a Patient Support Programme, and you would likely get several different answers — none necessarily wrong, but none complete on its own. For some, it is a helpline. For others, a home-nursing network, a reimbursement hotline, or an app that reminds patients to take their medicine. The European Medicines Agency’s definition, centred on the organised collection of information on medicinal product use for pharmacovigilance purposes, captures one important dimension of this activity¹. In practice, PSPs typically encompass a considerably broader range of support for patients and healthcare professionals.
A recent systematic review of Patient Support Programmes across Europe found evidence suggesting that these programmes may support treatment adherence, clinical outcomes and patient satisfaction, while also highlighting how differently these programmes are designed, defined and measured from one country to another².
That diversity matters. Not every PSP starts from the same point, and the strategic questions facing a programme at launch are not necessarily the same as those facing an established programme several years later.
TWO JOURNEYS, ONE PURPOSE
In our experience, the strategic starting point of a PSP is closely linked to where the product sits in its lifecycle.
A therapy entering a market for the first time faces a different set of questions from a programme that has already been running across several countries and now needs to evolve.
We tend to see two distinct journeys.
The first is launch. Here, there is no existing programme to build from: understanding the product’s competitive positioning and how a service can support diagnosis, build awareness and establish relationships with the centres and professionals that matter to the therapeutic area.
The second is scale-up, where the starting point is an existing programme already active in the market. At this stage, strategic priorities often shift towards maintaining market share as the product matures and new competitors or innovations enter the field. Here, the focus is on understanding what is already working, identifying where opportunities are being missed, and achieving greater consistency and efficiency across markets.
The two approaches have different priorities, but they share one important principle: the service should complement and reinforce the business strategy, while remaining focused on the support needs of patients and HCPs.
DESIGNING FROM A BLANK PAGE: THE LAUNCH MODEL
When a therapy is new to the market, particularly in rare disease and specialty areas, one of the central challenges can be awareness — and, more specifically, the time it takes to reach a diagnosis. Across Europe, people living with a rare disease wait an average of nearly five years between the onset of symptoms and a confirmed diagnosis, while more than half wait longer than six months simply to reach a relevant first medical contact³.
This has direct implications for how the PSP itself gets planned: ideally as part of the launch strategy from the outset, rather than as a separate decision made once that strategy is already in place.
The starting point is therefore the product and its positioning. What awareness needs to be built, and among whom? Which relationships with diagnostic centres and specialists could help shorten the path to diagnosis? What data generated through the programme could help accelerate the collection of real-world evidence over time?
Experience with rare disease registries shows the value that longitudinal, patient-level data can have when collected close to diagnosis. Such data can continue to inform regulators, payers and clinicians well beyond the initial launch period⁴,⁵. Patient Support Programmes may also generate information on how treatments are used in everyday practice, potentially contributing to both safety understanding and wider decision-making⁶.
Seen this way, a launch-stage PSP is more than a delivery mechanism for patient support: properly designed, it becomes an essential part of the product launch strategy.
REFINING WHAT ALREADY WORKS: THE SCALE-UP MODEL
An established PSP raises a different set of questions.
Programmes that have developed organically across European markets often reflect the circumstances in which they were created. A service established in one country under different circumstances may look quite different from the programme supporting the same therapy elsewhere, for many good reasons: regulation, healthcare system organisation, business priorities may vary largely from country to country. Over time, this can result in duplication, inconsistent patient experiences and limited opportunities to share learning between markets.
The focus therefore shifts from what needs to be built to what is already in place — and how well it is working.
Benchmarking and continuous support of actual unmet needs and business priorities assessment become particularly valuable here. It means identifying which practices are delivering value in individual markets, comparing internal and external best practices, and using that existing knowledge and experience across markets to tackle actual market and support needs. The result is less duplication and greater process and cost efficiencies across the wider programme footprint.
That does not mean making every country identical. Healthcare systems across Europe continue to differ in infrastructure, workforce capacity, financing and digital maturity⁷. National requirements around the collection and use of patient data add another layer of complexity⁸.
The opportunity lies in standardising where standardisation genuinely adds value: in quality standards, processes and, importantly, in how outcomes are measured and reported.
This becomes particularly relevant when evidence needs to be considered across multiple markets. If individual programmes use different metrics, formats and reporting intervals, it becomes difficult to build a coherent picture of performance across the European footprint. The systematic review of PSPs in Europe highlighted the lack of shared definitions and outcome measures as an important limitation in the existing evidence base².
For an established programme, scale-up is less about doing more than about making what already exists more coherent, more efficient and more useful.
One Underlying Logic
Launch and scale-up may begin from different questions, but the underlying logic remains the same: start with the product and market strategy, then translate that strategy into the service.
A PSP does more than deliver a set of operational activities: it is one of the ways a company’s strategic choices become visible in the everyday experience of patients and healthcare professionals — how people reach treatment, how they are supported once they start it, and how the organisation learns from the experience.
The balance between consistency and local relevance is particularly important across Europe. Regulatory and healthcare systems differ, and attempts to impose a single model can create as many problems as they solve. At the same time, allowing every market to develop independently can make it difficult to share learning or generate comparable evidence.
A similar tension appears in efforts to harmonise pharmaceutical regulation across borders, where convergence toward shared standards has tended to work best when pursued gradually rather than imposed uniformly⁹.
The role of the strategic partner therefore goes beyond delivering the individual components of a programme.
A supplier that starts the conversation with staffing models, call-centre capacity or logistics is addressing the execution of the service. A strategic partner should be able to start further upstream: understanding the market, the competitive context and the objectives of the product, and then translating those considerations into a service model that can work in practice.
That is a different conversation.
BEYOND THE TASK LIST
The operational complexity of PSPs makes it tempting to evaluate potential partners through operational measures alone: how many nurses are available, how many countries can be covered, how quickly can the programme be scaled?
These questions matter. But they should not be the first ones asked.
For a programme with a European footprint, the choice of partner can influence much more than execution. The right partner can contribute to the thinking that takes place before the service is designed: challenging assumptions, comparing what is happening across markets, identifying opportunities for greater consistency and helping translate strategic objectives into something that can actually be delivered locally.
Either way, the distinction is between a vendor that executes a predefined task list of activities and a partner capable of assessing the business strategy, setting service strategy priorities and devising a service strategy coherent with that business strategy — on top of outlining the service offering and standards needed to meet those priorities.
THE REAL QUESTION
Perhaps the real question is not only at which stage a PSP is — launch or scale-up — but whether it is still aligned to market conditions, unmet needs and business priorities.
A programme may have been designed appropriately for the moment it was launched. But markets change, healthcare pathways evolve and the needs of patients and HCPs do not necessarily remain the same.
Equally, a launch strategy should not end at launch. The programme created today will eventually become an established service, with its own data, experience and opportunities for optimisation.
The distinction between launch and scale-up is therefore more than a question of timing. It is a reminder that Patient Support strategy needs to evolve with the product, the market and the people it is intended to support.
REFERENCES
- European Medicines Agency. Guideline on Good Pharmacovigilance Practices (GVP) – Module VI: Collection, Management and Submission of Reports of Suspected Adverse Reactions to Medicinal Products (Rev 2). Amsterdam: EMA; 2017. (https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports-suspected-adverse-reactions-medicinal-products-rev-2_en.pdf)
- Sacristán JA, Artime E, Díaz-Cerezo S, Comellas M, Pérez-Carbonell L, Lizán L. The Impact of Patient Support Programs in Europe: A Systematic Literature Review. Patient. 2022;15(6):641-654. (https://www.researchgate.net/publication/361442269_The_Impact_of_Patient_Support_Programs_in_Europe_A_Systematic_Literature_Review)
- Faye F, Crocione C, Anido de Peña R, Bellagambi S, Escati Peñaloza L, Hunter A, et al. Time to Diagnosis and Determinants of Diagnostic Delays of People Living with a Rare Disease: Results of a Rare Barometer Retrospective Patient Survey. Eur J Hum Genet. 2024;32:1116-1126.
- Klein TL, Bender J, Bolton S, Collin-Histed T, Daher A, De Baere L, et al. A Rare Partnership: Patient Community and Industry Collaboration to Shape the Impact of Real-World Evidence on the Rare Disease Ecosystem. Orphanet J Rare Dis. 2024;19:262.
- Mistry PK, Kishnani P, Wanner C, Dong D, Bender J, Batista JL, Foster J. Rare Lysosomal Disease Registries: Lessons Learned Over Three Decades of Real-World Evidence. Orphanet J Rare Dis. 2022;17:362.
- Palffy E, Lewis DJ. Real-World Evidence Revelations: The Potential of Patient Support Programmes to Provide Data on Medication Usage. PLoS One. 2024;19(2):e0295226.
- OECD/European Union. Health at a Glance: Europe 2022: State of Health in the EU Cycle. Paris: OECD Publishing; 2022.
- Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016. Official Journal of the European Union. 2016;L119:1-88.
- Dangy-Caye A, Mousset A, Kermad A, Bouché-Bazerolle L, Bujar M, De Lucia M-L, McAuslane N, Lumsden R. Harmonizing Health: A Global Analysis of Pharmaceutical Regulatory Activities by International Regulatory Organizations. Front Med. 2025;12:1636269.


